Introduction: Ustekinumab (UST) is a fully human immunoglobulin G1 mAB antagonist to IL-12/23p40 for moderately to severely active ulcerative colitis (UC). The ongoing UNIFI long-term extension (LTE) evaluates subcutaneous (SC) UST through 220wks of maintenance treatment, with efficacy (wk92) and safety (wk96) results for patients treated in the LTE reported here. Aims & Methods: 783 patients entered the maintenance study, including 523 intravenous (IV) UST induction responders in the primary population (randomized to SC placebo [PBO]; n ¼ 175, UST 90 mg every 12 weeks [q12w]; n ¼ 172, or UST 90 mg q8w; n ¼ 176). Non-randomized patients included UST delayed responders (patients in clinical response to UST following an IV & SC UST dose) who received SC UST 90 mg q8w and PBO responders who received SC PBO. All patients completing wk44 were eligible to enter the LTE. PBO patients were discontinued after wk44 unblinding. Efficacy measures (i.e. partial Mayo scores and fecal inflammatory biomarkers) were collected every 12wks, thereafter at each dosing visit. Safety was evaluated throughout. Results: 588 patients were treated in the LTE, including 284 receiving SC UST and 115 receiving SC PBO in the randomized population and 116 UST delayed responders and 73 PBO responders. Rates of discontinuation before wk96 among randomized patients treated in LTE were 8.5% for UST and 40.9% for PBO. Among randomized patients who continued to receive UST in the LTE, percentages of patients in symptomatic remission from wks44 to 92 or up to the time of dose adjustment (as observed) ranged from 72.1% to 81.9% in the q12w group and 77.3% to 87.6% in the q8w group; percentages in partial Mayo remission ranged from 72.1% to 83.8% and 78.0% to 89.4%, respectively. In the ITT analysis of patients who were treated in the LTE, 60.6% and 62.0% of patients in the combined UST group attained symptomatic and partial Mayo steroid-free remission, respectively, at wk92 (Table) (PK), and evaluate efficacy and safety in a mixed population of active CD (Crohn's Disease Activity Index [CDAI] score of 220 to 450) and ulcerative colitis (UC) (total Mayo score of 6 to 12 with endoscopic subscore of !2). After loading doses of IV 5 mg/kg at Weeks 0 and 2, patients were randomised at Week 6 to receive either SC 120 mg (580 kg) or 240 mg (!80 kg) every 2 weeks (SC arm), or IV 5 mg/kg every 8 weeks (IV arm). The primary PK endpoint, C trough,week22 (pre-dose serum concentration at Week 22), was analysed by using analysis of covariance (ANCOVA). The NI of SC (120 mg and 240 mg combined) was predefined to be met if the lower bound of the 2-sided 90% confidence interval (CI) for the ratio of the geometric least square (LS) means was higher than 80%. Comparative clinical efficacy and safety profiles were assessed for both arms.
Note: Randomisation at Week 6 to treatment assignment was stratified by concomitant use of immunomodulators, disease (CD or UC), clinical response at Week 6 (responder or nonresponder by CDAI-70 for CD and partial Mayo score for UC), and body weight at Week 6 (580 kg or !80 kg). Contact E-Mail Address: stappenb@wustl.edu Introduction: Mucosal biomarkers have been shown to identify responders to anti-TNF and anti-integrin therapies in Crohn's Disease (CD) patients. We have recently identified a novel epithelial biomarker of malabsorption, microvilli (MV) length, to be significantly reduced in CD patients. We hypothesize that malabsorption contributes to the development of intestinal inflammation and therefore may have predictive value for clinical and endoscopic response to biologic therapy in CD patients. Ustekinumab (UST) is an anti-IL12/23 monoclonal antibody approved for the treatment of CD. Aims & Methods: The aim of this study was to determine the predictive value of pre-treatment ileal biopsy MV length for clinical and endoscopic response to UST in CD patients. Biopsy samples from the American cohort of UNITI-2 trial patients were stained for H&E and analyzed for MV length. Clinical response, defined as a reduction of CDAI of !100 points from pre-treatment baseline, clinical remission, defined as CDAI 5 150, and endoscopic response, defined as !50% reduction from baseline SES-CD score, at 8 weeks post-induction were assessed. The primary outcome was clinical response to UST stratified by reduction in pre-treatment MV length, using a threshold of 1.7 mm (normal above, low below). Outcomes were compared using Fisher exact tests for subgroups and likelihood ratio tests for tests of effect modification. Results: A total of 106 CD patients from UNITI-2 (placebo ¼ 36, UST ¼ 70) with biopsies were stained, of which 95 patients (90%) had sufficient samples for analysis of MV length. There were no significant differences in baseline patient characteristics between placebo-(N ¼ 36) and UST-treated (N ¼ 70) patients (Table 1) . As a continuous variable, MV length was an effect modifier of clinical response to UST therapy (p ¼ 0.043).The overall clinical response was significantly higher in the UST-treated group compared with placebo: 65% (40/62) vs. 39% (13/33, p ¼ 0.03). The greatest therapeutic effect and differences were seen in the normal MV length group: clinical response UST vs. placebo, 85% (11/ 13) vs. 20% (1/5, p ¼ 0.02); corresponding rates in the low MV length group were 59% (28/49) vs. 46% (12/28, p ¼ 0.17). Similar results were seen with respect to endoscopic response: normal MV length group (75% [6/8] Contact E-Mail Address: jjliu@uams.edu Introduction: Several mucosal biomarkers have been identified to hold predictive values for biologic therapies in Crohn's disease (CD). Vedolizumab is an antiintegrin monoclonal antibody approved for the treatment of CD. We have recently shown that ileal epithelial cell pyroptosis, a biomarker of innate immune activation, can help identify responders to vedolizumab therapy in CD. Ileal epithelial cell microvilli length (MVL), a novel biomarker of malabsorption, was shown to be significantly reduced in CD patients and may also have predictive value for biologic treatment. The utility of using the combination of these two biomarkers to predict response to vedolizumab therapy in CD is unknown.
Aims & Methods:
The aim of this study was to determine the relationship between ileal epithelial cell pyroptosis and ileal MVL and whether the combination of these two biomarkers may improve the identification of responders and nonresponders to vedolizumab in CD. Patients aged 18 to 80 years with known diagnosis of CD from five American IBD centers with pre-vedolizumab ileal biopsies were enrolled. Clinical response, defined as a reduction of HarveyBradshaw Index (HBI) of !5 points from pre-treatment baseline, and clinical remission, defined as HBI 55, was determined !6 months after therapy. Biopsy samples were sectioned and stained for pyroptosis using the Maximus Biological Assay kit (Maximus Diagnostics LLC). Ileal MVL was taken as the average of 50 measurements obtained from 10 intact villi per patient on H&E stained sections, at 100Â magnification by a blinded pathologist. Clinical response rates to vedolizumab stratified by pre-treatment MVL were examined. The relationship between ileal pyroptosis and MVL was described using Spearman's correlation. The value of ileal pyroptosis and/or MVL thresholds alone or in combination for prediction of clinical response was compared using Fisher's exact test.
Results: 55 CD patients with pre-treatment ileal biopsies were enrolled; 43 had adequate samples for analysis of both epithelial cell pyroptosis and MVL. The overall clinical response rate was 58% (25/43). There were no significant differences in baseline patient characteristics, disease characteristics, and concomitant medication use between responders (N ¼ 25) and non-responders (N ¼ 18). As a single biomarker, ileal MVL range of 1. Contact E-Mail Address: pumun@hotmail.com Introduction: Ustekinumab is a fully human monoclonal antibody that blocks the p40 subunit of interleukin 12/23. Ustekinumab is effective for induction and maintenance of remission in adult Crohn's disease (CD) but data in paediatric CD is scarce. This study aims to describe the effectiveness and safety of ustekinumab in refractory paediatric CD patients in a European multi-centre cohort in real-life practice. Aims & Methods: The aim of our study was to describe the effectiveness and safety of ustekinumab in refractory paediatric CD patients in a European multicentre cohort in real-life practice. Retrospective review of children with CD (2-18 years old) who were treated with ustekinumab (at least one dose) from centres worldwide affiliated with the Paediatric IBD Interest and Porto group of ESPGHAN. Primary outcome was corticosteroid (CS) and Exclusive Enteral Nutrition (EEN)-free remission (defined by wPCDAI (weighted Paediatric Crohn's Disease Activity Index 5 12.5) and safety at week 6 and 52. Results: A total of 101 patients (23 centres, 10 countries) were included (51 males (50.4%), mean age at ustekinumab initiation 15.4 years (IQR 12.7-17.2), mean previous disease duration 4.3 years (IQR 2.5-6.8)). Sixty percent of the patients had ileocolonic involvement (L3) and 24.8% perianal disease. The median wPCDAI at ustekinumab initiation was 38.7 (IQR 25-57.5). Ninety-six percent were previously treated with anti-TNF (60.4% with two of them) and 22% had received vedolizumab. The most used induction strategy was an intravenous dose of 6 mg/kg (IQR 5-6) and in 79% of the patients maintenance strategy was based in 90 mg doses sc every 8 weeks. At week 6 (n ¼ 74) 38% of these patients achieved the primary outcome and at week 52 (n ¼ 49) 50% of patients maintained remission. We did not find any predictive factor associated with ustekinumab-induced clinical remission in our cohort in the multivariate analysis. No malignancies were reported during the follow-up (mean duration of ustekinumab treatment: 14.1 months (IQR 9.1-18.9)). Six minor adverse events (three infections, one infusion reaction, one abnormal laboratory result, one vasculitis of the tongue) and seven patients with clinical deterioration due to the disease (three of them requiring hospitalization) were reported. One patient died by an unrelated ustekinumab cause during the follow-up.
Conclusion: This is the largest cohort of ustekinumab use in paediatric CD patients thus far. Despite its retrospective nature and the lack of standardized treatment, we demonstrate that ustekinumab was effective and safe in a subcohort of refractory paediatric CD patients at short and mid-term follow-up. Larger cohorts as well as prospective studies are needed to confirm these results at long-term follow-up. Disclosure: Nothing to disclose. Previous presentation of the maintenance study results reported data for all patients who were randomized to subcutaneous (SC) maintenance treatment regardless of induction treatment received. Here, we present results from the maintenance study by subgroups of individual UST IV induction dose. Aims & Methods: UC patients who failed conventional or biologic therapy (including anti-TNFs and/or vedolizumab) were randomized to receive a single IV induction dose of placebo (PBO) or UST 130 mg or $6 mg/kg (260 mg for weight 55 kg, 390 mg for weight 455 kg and 85 kg, or 520 mg for weight 485 kg) at induction baseline (Week 0). Patients who were in clinical response 8 weeks after UST IV induction were randomized to SC PBO, UST 90 mg q12w, or UST 90 mg q8w at maintenance baseline. The primary endpoint in the maintenance study was clinical remission at maintenance Week 44 (52 weeks after IV UST induction); key secondary endpoints were maintenance of clinical response, endoscopic improvement, corticosteroid-free clinical remission, and maintenance of clinical remission among patients who achieved clinical remission at maintenance baseline. Maintenance data are presented for subgroups of patients by induction dose (130 mg or $6 mg/kg), comparing maintenance UST SC with PBO. The maintenance study was not powered to compare clinical outcomes in these subgroups. Results: Among patients who received UST $6 mg/kg IV induction at Week 0 and responded at Week 8, greater proportions of patients who were randomized to receive UST SC maintenance were in clinical remission at Week 44, maintained clinical response through Week 44, achieved endoscopic improvement at Week 44, and were in clinical remission and not receiving corticosteroids at Week 44 compared with patients randomized to PBO SC maintenance (Table 1) . Among patients who received UST 130 mg IV induction at Week 0 and responded at Week 8, differences between UST and PBO SC maintenance were smaller than those observed in the $6 mg/kg group. Among patients who were in clinical remission at maintenance baseline, numeric differences between UST and PBO SC maintenance groups in the percentage of patients who maintained clinical remission through Week 44 were also seen, with larger differences observed in patients who received $6 mg/kg induction than those who received the 130 mg induction. Conclusion: Patients who received UST $6 mg/kg IV induction followed by UST SC maintenance had better clinical outcomes after 1 year than those who received UST $6 mg/kg IV induction followed by PBO SC maintenance. These results suggest that the $6 mg/kg is the optimal induction dose, when combined with UST maintenance treatment, to achieve clinical benefit in patients with moderately to severely active UC. Patients who were in clinical response to ustekinumab IV induction dosing and were randomized to placebo SC on entry into this maintenance study. b Patients who were in clinical response to ustekinumab IV induction dosing and were randomized to ustekinumab SC 90 mg q12w or q8w on entry into this maintenance study. If low-grade dysplasia (LGD) is detected, surveillance is intensified. Current surveillance strategies lead to many unnecessary endoscopies for patients who do not develop neoplastic progression. The longitudinal course (i.e. successive measurements) of histological diagnosis and immunohistochemical biomarkers has been shown to be associated with neoplastic progression. This enables a more personalised and risk-based surveillance strategy. In this study we aimed (1) to define the performance of personalised dynamic surveillance intervals in terms of harms, benefits, and costs, and (2) to compare these with fixed intervals, as currently recommended by the guideline. Aims & Methods: We fitted a multivariate joint model with LGD, p53, and SOX2 as predictors for high-grade dysplasia (HGD) or oesophageal adenocarcinoma (OAC), analysing a multicentre prospective cohort study of 631 BO patients. 1 The discriminative power of the model between patients with low and high neoplastic progression risk was estimated by using the area under the receiver operating curve (AUC), adjusted for optimism. This prediction model was used to define risk-based surveillance schedules with four neoplastic progression risk cut-offs: 1.5%, 2.0%, 2.5%, and 3.0%. The next endoscopy could be scheduled at the time point that the neoplastic progression risk reached this threshold. The delay in years between true neoplastic progression time, rather than the time of detection, was estimated by simulation for each cut-off. Besides, we estimated the number of surveillance endoscopies and mean costs per patient. All parameters were compared with the performance of the fixed schedule as currently recommended by the guideline. Results: The personalised prediction model could discriminate well between low and high-risk patients with AUC ranging 0.80-0.88 during follow-up. The strategy with the best balance between harms (number of endoscopies) and benefits (finding neoplastic progression early) was the personalised schedule, in which the next surveillance endoscopy would be planned at the time point that the neoplastic progression risk was 2.5% (Table) . Compared with the current guideline of fixed intervals, in this personalised strategy a median of three endoscopies per patient in a lifetime could be saved in those who would never progress to HGD/ OAC. At the same time, there was no need to perform more endoscopies or to have a longer delay in detection of HGD/OAC, in patients who would progress. This indicated a reduction in mean costs of E2,733 per patient in our cohort (E1.7 million in total) compared with current guideline recommendations. Conclusion: Given the good discriminative power between patients with a low and high neoplastic progression risk, and an excellent balance between harms and benefits, this personalised dynamic surveillance strategy is likely to reduce the patient and healthcare burden in BO surveillance. After further validation, this personalised strategy may be worthwhile to be implemented in the current guideline. Disclosure: Nothing to disclose. 
LB09 FIRST IN-HUMAN (FIH) STUDY ON THE SAFETY, TOLERABILITY AND EFFICACY OF THE AQUAMEDICAL FOCAL RF-VAPOR ABLATION (RFVA) SYSTEM, FOR THE ERADICATION OF BARRETT'S ESOPHAGUS (BE)
S. Contact E-Mail Address: s.n.vanmunster@amc.uva.nl Introduction: Radiofrequency ablation (RFA) has become the preferred modality for ablation of dysplastic BE. Although highly effective, RFA has drawbacks such as the need for multiple deployment steps; for contact with the esophageal wall; and for multiple treatment endoscopies. Aqua RFVA System (AquaMedical, Santa Anna, CA) is a novel ablation system that generates vapor/steam at 100 C using an RF electrode at the catheter tip to ablate tissue. It has been designed to address many of the limitations of current ablation techniques. We aimed to develop dosimetry using in-vitro lean-beef, acute and subacute porcine models and test the feasibility, safety and efficacy in patients with flat dysplastic BE. Aims & Methods: Aqua system includes an RFVA generator (60 W), a 7Fr RFVA catheter and a syringe with saline. The catheter is passed through the biopsy channel of a standard endoscope with distal attachment cap and is used to create focal ($1 cm 2 ) ablations in the esophagus. The RFVA system was tested in three successive phases; a benchtop lean-beef model; a porcine study (n ¼ 6); and an ongoing, FIH study (n ¼ 15). In the lean-beef and porcine experiment, ablation depth using the RF-VA system at different dosages (dose ¼ duration of vapor delivered in seconds) was compared with ablation depth for focal RFA (1-4 Â 12 J/cm 2 ) at acute (0 h) and subacute (48 h) setting. Based on these results, two doses were selected for further testing in the FIH study, including patients with flat dysplastic BE. Per-patient, 4 ablations (2/dose) were applied at 1 cm distance. Patients were followed post-ablation and symptoms and AEs were recorded. Repeat EGD with histology was performed after 6-8 weeks to assess the rate of conversion to squamous epithelium. Results: None of the treatments in all study-phases resulted in any complications. As expected, in the lean-beef model (total 10 ablations/modality/dose), increasing doses of RFVA and increasing numbers of RFA applications both resulted in increasing depth of ablation. The range of ablation depth with 2-5 s Vapor (0.75 mm-1.5 mm) was comparable to 1-4 Â RFA applications (0.58 mm-1.5 mm). In acute porcine evaluation (total 42 Vapor ablations), no differences were found for all doses and treatments tested (3/5 s Vapor and 1-2 Â RFA). However, as the treatment effect evolved over the following 48 (total 60 Vapor ablations), a 3 s RFVA was comparable to 2 Â RFA, whereas 5 s RFVA produced slightly deeper ablation. We selected a conservative 1 s and 3 s dose for human testing. In this ongoing FIH phase, a total of 42 RFVA were technically successful applied in 12 patients. No adverse events occurred and the procedure was well tolerated, with pain scores ranging from 0-1 out of 10 during 14 days post treatment. Follow-up endoscopy was performed in 6 patients with 24 ablations and showed a median squamous conversion rate for the 1 s and 3 s ablations of 73% (IQR 0-100) and 98% (IQR 0-100), respectively. Histologic analysis from all biopsies obtained from endoscopically eradicated areas, confirmed normal squamous epithelium without buried BE glands. Conclusion: In this 3-phase study with lean-beef, porcine and the first in-human application, the Aqua RFVA system was safe for esophageal ablation and successfully converted dysplastic BE into squamous epithelium. These preliminary yet promising results warrant further testing with RFVA devices. Disclosure: Nothing to disclose.
LB10 CLINICAL IMPACT OF ENDOSCOPIC ULTRASOUND-GUIDED THROUGH-THE-NEEDLE MICROBIOPSIES IN PATIENTS WITH PANCREATIC CYSTS -A PROSPECTIVE SINGLE-CENTER STUDY
B. Kovacevic Contact E-Mail Address: bojan.k@dadlnet.dk Introduction: Previously, results of EUS-guided through-the-needle biopsies (TTNBs) from pancreatic cystic lesions (PCLs) have been reported in several, mainly retrospective studies. [1] [2] [3] [4] [5] While the technique is associated with high technical success and diagnostic yield, there is a lack of evidence concerning its added diagnostic value. Furthermore, there is conflicting evidence regarding the rate of adverse events, the most common of which being acute pancreatitis. Aims & Methods: The primary aim of this prospective single-center study was to estimate the clinical impact of TTNBs. Between February 2018 and August 2019, we included consecutive patients presenting with a PCL of 15 mm or above referred for EUS examination. Technical success was defined as successful puncture of the lesion with an FNA-needle and acquisition of at least one macroscopically visible biopsy, whereas diagnostic yield was defined as the proportion of the patients where a histological diagnosis was established. Cytological samples were rated according to Papanicolaou Society of Cytopathology guidelines, 6 ROSE was not performed. Adverse events were defined according to current ASGE lexicon. 7 Demographic and lesion data, together with procedural variables of interest were recorded. Logistic regression and appropriate univariate analyses were performed exploring possible predictors of adverse events. Results: One hundred and one patients were included. Fifty-four of the patients (53.5%) were female, and mean age was 67.9 (SD 9.9). High-risk stigmata were observed in three patients (3.0%), whereas 53 patients (52.5%) had at least one worrisome feature. Technical success was high (n ¼ 95, 94.1%). Diagnostic yield of TTNB was higher compared with FNA-cytology, 77.1% and 31.4% respectively (p 5 0.001). Procedural data and adverse events are presented in Table 1 . Adverse event rate did not change significantly following introduction of aggressive perioperative hydration with Ringer lactate and rectal NSAIDs (17.6% vs. 8.3%, p ¼ 0.366). Statistical analyses did not reveal any procedural or demographic variables to be associated with adverse events. Additional diagnostic yield of TTNB, leading to change in clinical management, was 11.9%. Of these, a diagnosis of SCN was made in 10 cases, leading to discontinuation of follow-up. In the remaining two cases, a diagnosis of MCN and IPMN was made in spite of low CEA concentration in cyst fluid (0 and 14 mg/L respectively). Thirteen patients underwent surgical resection, and the concordance rate between TTNB and surgical specimen diagnosis was 89%.
Conclusion: TTNBs had an additional diagnostic yield of 11.9% compared with FNA-cytology and cross-sectional imaging, resulting in important change of clinical management. However, the procedure seems to be associated with severe adverse events and a substantial overall adverse event rate of 9.9%. Further studies will show the proper indications of TTNB and in which subgroup of patients the clinical implication will outweigh the risk. Disclosure: Nothing to disclose. Results: 61 patients in three tertiary referral centers were consecutively screened and enrolled from May 2017 to December 2018. The study was ended after reaching the primary endpoint and ended at 6 months follow-up of the last enrolled patient. 32 were randomized to SA and 29 to CA. Demographic and baseline characteristics were equally distributed in both arms. In the CA 44.8% completed the study without malignancy and 48.2% with malignancy. In the SA 25% completed the study without malignancy and 68.8% with malignancy. Diagnostic Accuracy of Histopathology: Tissue samples could be obtained in all cases at first evaluation. In the SA one sample was inadequate for histological analysis resulting in a yield of SOC on first sample of 96.8%. In the CA brushings were adequate for cytological analysis in all patients. In one participant in the CA the proceduralist suspected a stone as a reason for the stricture with no wire passage being possible. In this case SOC was used and visualized a stone which was not seen on prior imaging and successfully treated with SOC-guided electrohydraulic lithotripsy. No brushings were performed in this case. First sample sensitivity of SOC guided biopsies were significantly higher than ERCP guided brushing (SA 68.2% vs. CA 21.4%, p ¼ 5 0.01). All other parameters such as specificity, positive predictive value, negative predictive value and overall accuracy showed no significant difference. Impact of visual impression: Only one lesion in the SA could not be visualized. In approximately half of the cases in both arms the visual impression had an impact on the patient management (CA 50% vs. SA 56.7%; p ¼ 0.62). The sensitivity (SA 95.5% vs. CA 64.3%; p ¼ 0.01), overall accuracy (OA) (SA 87.1% vs. CA 62.1%, p ¼ 0.03) and PPV (SA 100% vs. CA 81.8%, p ¼ 0.04) were significantly higher in the SA compared with the CA, while specificity and NPV showed no significant difference (Table 4) . Adverse Events: Mild adverse events occurred in three patients in the CA and in two patients in the SA, and could be successfully treated conservatively. Conclusion: In conclusion, SOC was shown to be safe and effective with a higher diagnostic sensitivity compared with standard ERCP and brushing for the diagnosis of indeterminate biliary strictures. The visual impression was shown to have a pertinent impact on patient management and should be an essential part of determining the correct diagnosis. SOC should be considered as a viable diagnostic alternative to conventional ERCP for indeterminate biliary strictures with the potential to change patient management. Disclosure: Nothing to disclose. Comparative effectiveness of biliary brush cytology and intraductal biopsy 3, 4 improved guideline compliance cannot guarantee prevention of exogenous duodenoscope-based transmission of infection. 5 Employing single-use duodenoscopes is an alternative strategy to avoid contamination associated with endoscope reuse. A new single-use duodenoscope recently showed comparable performance to three models of reusable duodenoscopes in an ERCP bench simulation study. Performance of the new device should be tested clinically. Aims & Methods: This Ethics Committee-approved study aimed to assess the safety and feasibility of ERCP using the first-generation EXALT Model D single-use duodenoscope (Boston Scientific, Marlborough, MA; NCT03701958) in adult patients at six academic medical centers. Seven ERCP experts enrolled consecutive adults without altered anatomy who were scheduled for a clinically indicated ERCP. ''Roll-in'' testing consisted of navigation to and visualization of the duodenal papilla, followed by ERCP with a reusable duodenoscope. After successful completion of roll-in cases, a separate group of patients was enrolled for the ERCP procedural study. Endpoints were ability to complete the roll-in or ERCP, incidence of crossover from single-use duodenoscope to reusable duodenoscope, procedure-related serious adverse events assessed at 72 hours and 7 days, and endoscopist ratings of satisfaction with the single-use duodenoscope. Results: Seventy-three patients participated as roll-in (n ¼ 13) or ERCP (n ¼ 60) cases in a consecutive case series in April and May 2019. Of the 60 patients who had an ERCP, 37 (61.7%) were male, mean age was 64.0, 44 (73.3%) had a prior ERCP and 43 (71.7%) had a known prior sphincterotomy. American Society for Gastrointestinal Endoscopy (ASGE) procedural complexity scores were Grade 1 (least complex) for seven (11.7%), Grade 2 for 26 (43.3%), Grade 3 for 26 (43.3%), and Grade 4 (most complex) for one (1.7%) cases. All 13 (100%) roll-in cases were completed without crossover to a reusable duodenoscope. All 60 (100%) ERCPs were completed, 58 (97%) using the single-use duodenoscope only, and 2 (3%) with crossover to a reusable duodenoscope. The most common ERCP indications were for management of biliary stent (n ¼ 33, 55.0%), evaluation of biliary stricture (n ¼ 16, 26.7%), and bile duct stone clearance (n ¼ 11, 18.3%). One crossover case required pancreatic endotherapy in which pancreatic duct (PD) cannulation failed with the singleuse and a reusable duodenoscope; PD cannulation ultimately succeeded using needle-knife sphincterotomy. In another crossover case, dilation of a tight hilar biliary stricture in a patient with primary sclerosing cholangitis failed with the single-use duodenoscope, then succeeded with a reusable duodenoscope. Among the 73 patients, three (4.1%) experienced mild or moderate post-ERCP pancreatitis, one (1.4%) had a serious postsphincterotomy bleed, and one (1.4%) with walled-off pancreatic necrosis and pre-existing infection worsened after PD stent placement. Median overall satisfaction with the single-use duodenoscope was Contact E-Mail Address: wangpuhuaxi@qq.com Introduction: Computer-aided detection (CADe) of colon polyps has been demonstrated to improve colon polyp and adenoma detection during colonoscopy by alarming the location of polyps on a parallel monitor simultaneously. While the video flow on the two monitors are duplicate, the aim of this study was to investigate whether embedding this CADe system into regular colonoscopy could increase polyp and adenoma detection and without increasing physician fatigue level. Aims & Methods: Consecutive patients presenting for diagnostic and screening colonoscopies were prospectively randomized to undergo routine colonoscopy with or without the assistance of the previously validated real-time polyp detection CADe system which provides a simultaneous visual notice and sound alarm when a polyp was detected. The fatigue level was evaluated from score 0-10 by the performing endoscopists after each colonoscopy procedure. The main outcome was adenoma detection rate (ADR). Results: Out of 790 patients analyzed, 397 were randomized to routine colonoscopy (control group), and 393 to a colonoscopy with computer-aided diagnosis (CADe group). A total of 625 polyps, 304 adenomas and 12 serrated adenomas were detected. The polyp detection rate (PDR) of the control and CAD groups were 33.25% and 47.07% respectively (OR ¼ 1.786, 95% CI 1.339-2.381, P 5 0.001). The adenoma detection rates (ADR) were 20.91% and 29.01%, respectively (OR ¼ 1.56, 95% CI 1.129-2.158, P ¼ 0.009). The average number of polyps per colonoscopy (PPC) were 0.51 and 1.07, respectively (Change Contact E-Mail Address: silviapagg@gmail.com Introduction: Linked-Colour Imaging (LCI), a new image-enhanced technology that emphasizes contrast in mucosal colour, has been demonstrated to substantially reduce the miss rate of polyps as compared with standard White-Light (WL) in tandem colonoscopy studies. Whether LCI increases adenoma detection rate (ADR) is still uncertain. Aims & Methods: Consecutive subjects undergoing colonoscopy following a positive faecal immunochemical test (FIT) in the context of regional populationbased colorectal cancer screening programmes were randomised (ratio 1:1) to undergo colonoscopy with either LCI or WL. Insertion and withdrawal phase of colonoscopy were both carried out using the same assigned light. Experienced endoscopists from seven Italian centres participated in the study. Randomisation was stratified by gender, age group and screening round, using a randomised blocks design. The planned sample size (300 subjects in each arm) could allow for an 80% power to detect as statistical significant ( ¼ 0.05; two-sided test) a 11.5% and 10.5% absolute increase in the detection rate of adenomas and advanced adenomas. The primary outcome measure was the proportion of patients with at least one adenoma (ADR). Results: Of 704 eligible subjects, 649 were randomised to either LCI (n ¼ 326) or WL (n ¼ 323) colonoscopy and included in the analysis. Overall, 48.9% of patients were male, the mean age AE SD was 60.8 AE 7.3 years, and 32.5% were at first FIT round, with no differences between the two study arms. The ADR was higher in the LCI group (185/ 326 patients, 56.5%) than in the WL group (151/323 patients, 43.5%) (p ¼ 0.047; RR for LCI: 1.22, 95%CI 1.03 to 1.43). The proportion of patients with advanced adenomas and sessile serrated polyps was 26.1% and 8.7% in the LCI arm, and 22.0% and 5.0% in the WL arm, respectively (p ¼ NS for both comparisons). Multivariate analysis showed that factors independently influencing ADR were the use of LCI, male gender, age greater than 60 years, and adequate (Boston bowel preparation scale !6) bowel preparation (Table 1) . At perpolyp analysis, the mean number of adenomas per patient was 1.12 AE 1.59 and 0.98 AE 1.47 in the LCI and WL group, respectively (p ¼ NS). Conclusion: In FIT-positive patients undergoing screening colonoscopy, the routine use of LCI led to a significant increase in ADR. Disclosure: Nothing to disclose.
LB11 SINGLE-OPERATOR PERORAL CHOLANGIOSCOPY (SPYGLASSDS)-GUIDED BIOPSY VS. ERCP-GUIDED BRUSHING FOR INDETERMINATE BILIARY STRICTURES -
for detection of malignant biliary strictures: A systematic review and metaanalysis. Gastrointest Endosc 2015; 81: 168-176. 3. Draganov PV, Chauhan S, Wagh MS, et al. Diagnostic accuracy of conventional
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From eosinophilic oesophagitis to novel obesity therapies ) or placebo (PBO) cohorts. Symptoms were assessed using a validated, proprietary, daily EG/EGE patient-reported outcome questionnaire to generate a total symptom score (TSS). The primary endpoint was mean percent change in GI tissue eos counts from baseline (BL). Secondary endpoints were the proportion of treatment responders (defined as patients with both 475% decrease in tissue eos and 430% improvement in TSS), and mean percent change in TSS from BL. IRB approval was obtained.
Results: 59 patients were evaluable for efficacy (n ¼ 20 in HD; n ¼ 19 in LD; n ¼ 20 in PBO). BL characteristics were balanced between groups. For the primary endpoint, the AK002 groups had an overall 95% mean reduction of tissue eos relative to BL compared with a 10% mean increase in PBO (p 5 0.0001; Table 1 ). Tissue eos depletion to 6 eos/hpf was seen in 37 (95%) AK002 patients. There was significant improvement in TSS scores with AK002 compared with PBO (p ¼ 0.0012). Among all AK002 patients, 69% were treatment responders compared with 5% of PBO patients (p ¼ 0.0008). Among EG/EGE patients with concomitant EoE, significant histologic and substantial symptomatic improvements were reported with AK002 compared with PBO. The most common adverse events (AE) reported for AK002 were mild to moderate infusion related reactions (IRR), most common at the first infusion only. Contact E-Mail Address: mk8@grupo1492.com Introduction: Eosinophilic esophagitis (EoE) is an increasingly prevalent atopic condition characterized by eosinophilia of the esophageal mucosa and symptoms of esophageal dysfunction. Fluticasone use has been reported for EoE with formulations not designated for esophageal delivery. APT-1011, a novel fluticasone propionate orally disintegrating tablet formulation, is under investigation for the treatment of EoE. Aims & Methods: To evaluate the safety and efficacy of four dosing regimens of APT-1011 and select the dosing regimen with the best benefit to risk profile for further development. Methods: The FLUTicasone in EoE (FLUTE) trial was a randomized, doubleblind, placebo-controlled, multicenter, dose-ranging study of APT-1011 vs. placebo in adults diagnosed with EoE. Participants were enrolled from 71 sites in six countries in North America and Western Europe from September 2017 to October 2018. Participants were randomized to APT-1011 (1.5 mg HS; 1.5 mg AM and HS; 3 mg HS; or 3 mg QAM and HS) or matching placebo. The primary efficacy endpoint was histologic response at Week 12, as measured by percent of study participants with a peak of 6 eosinophils per high power field (eos/HPF) on at least five esophageal biopsies. Secondary endpoints assessed endoscopic activity and symptoms. Safety parameters were also assessed. (Clinicaltrials.gov NCT03191864; EudraCT Number: 2016-004749-10).
Results: At total of 103 patients were enrolled (mean age 38.6; 68.0% male; 97.1% white). An overall response rate of 70% was observed among all APT-1011-treated study participants, compared with 0% of placebo-treated study participants. Among the APT-1011 dose groups, the 1.5 mg BID dose yielded the highest histologic response rate (86.4%) (Table) . A total daily dose of 6 mg (3 mg BID) did not provide histologic benefit beyond the 3 mg daily dose (1.5 mg BID or 3 mg HS). Statistically significant improvements in endoscopic appearance were observed with all APT-1011 dosing groups compared with placebo, with the 3 mg HS dosing regimen showing the largest numerical improvement. The most common treatment-emergent adverse events were esophageal 8/85 (9.4%) and oral candidiasis 5/85 (5.9%) in subjects on APT-1011, compared with 0% on placebo. Most events of candidiasis were in the 3 mg BID dosing group (8/20; 40%). No subject experienced adrenal axis suppression based on adrenocorticotropic hormone simulation testing or symptoms of hypercortisolism. Conclusion: APT-1011 for 12 weeks is highly efficacious to induce histologic remission and is safe and well tolerated in adult patients with EoE. The 3 mg HS dose proved to have the best benefit to risk balance of efficacy and safety, with the added benefit of once daily dosing, for future development. Maintenance therapy for up to 52 Weeks is currently ongoing. Disclosure: Evan Dellon has received research funding from Adare, Allakos, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos, Regeneron, Shire; and consulting fees from Adare, Aimmune, Alivio, Allakos, AstraZeneca, Banner, Biorasi, Calypso, Celgene/Receptos, Enumeral, EsoCap, Gossamer Bio, GSK, Regeneron, Robarts, Salix, Shire; and educational grant from Allakos, Banner, Holoclara. Contact E-Mail Address: iradj.sobhani@aphp.fr Introduction: Sporadic colorectal cancer (CRC) is a result of complex interactions between the host and its environment. Environmental stressors act by causing host-cell DNA alterations (genetic and epigenetic changes). Interest of microbiota in mass screening for colon cancer has not been prospectively investigated. Aims & Methods: To (1) investigate the stressor ability of CRC-associated gut dysbiosis as causal agent of host DNA alterations in germ-free animals; (2) identify genetic and epigenetic changes in the colonic mucosa; (3) find out similar alterations in human donors; (4) validate data in human cohorts. Germ-free mice (approval ethical committee #12/076; n ¼ 185) received fresh fecal samples from nine subjects with normal colonoscopy and nine genderand age-matched CRC patients, and were monitored (7-14 weeks) after human fecal transfer (FMT). Aberrant crypt foci, luminal microbiota and DNA alterations (whole colonic exome sequencing and levels of gene methylation in tissues and effluents) were monitored following FMT by using Agilent Table reference : * Responder is defined as a subject with 6 peak eosinophils/high-power field (HPF). EREFs: Eosinophilic Esophagitis Endoscopic Reference Score; EoE: eosinophilic esophagitis; LS: least square; N: number uptake, weight of animals and blood routine tests were monitored. Fecal bacteria in animals were characterized (16sRNA) at baseline (human donors) and over time during the follow up. Associations between DNA (genetic, epigenetic) and stool bacteria were established by using appropriate bioinformatic methods. Significant associations were investigated in a human pilot study (n ¼ 266), and a panel of dysbiosis-related methylate genes was validated in asymptomatic (n ¼ 500) and symptomatic (n ¼ 500) individuals undergoing colonoscopy and followed up for 3-5 years. Human fecal microbiota was finally submitted to whole metagenomic sequencing for the identification of bacteria species associated with DNA alteration in the validation prospective (Clinical Trial NCT01270360). Results: After human FMT, CRC-associated microbiota induced higher numbers of ACF and higher hypermethylated genes in the mice colonic mucosa (vs. healthy controls' microbiota recipients) when no significant difference in DNA mutation was observed in between animal groups. As suggested by these data, in human effluents (blood and stools) and tissues from donors, several gene promoters including SFRP1,2,3, PENK, NPY, ALX4, SEPT9, WIF1 were found hypermethylated in human CRC individuals; the methylation status of these genes was associated with panel of bacteria whose abundances were significantly different versus healthy donors. In a pilot study (n ¼ 53 CRCs, 123 controls), the blood methylation levels of three genes (Wif1, PENK and NPY) were shown closely associated with dysbiosis. Consequently a cumulative methylation index (CMI) of these genes was constructed. In a prospective validation study (n ¼ 187 CRCs; 813 controls) with at least 3 years follow-up, the CMI of these genes is found significantly higher in CRC patients as compared with controls. The multivariate analysis that included also fecal immunochemical blood test (FIT) in asymptomatic individuals showed CMI as an independent risk factor for CRC diagnosis. Finally, fecal bacterial species in the validation cohort were identified based on their whole genome sequences and panel of pro epigenomic bacteria in stools was established.
LB17 MICROBIOTA DYSBIOSIS INDUCES COLORECTAL CANCER (CRC) THROUGH AN EPIGENETIC MECHANISM
Conclusion: CRC-related dysbiosis induces methylation rather than mutation in host genes. Promethylator bacteria are characterized in stools. Their quantification is useful for the identification of individuals with high risk of colon cancer. Promethylator dysbiosis can be used for the evaluation of probiotics in preventing colon cancer. Disclosure: Nothing to disclose. Contact E-Mail Address: ckelly2@bidmc.harvard.edu Introduction: In Celiac Disease (CD), gluten triggers an autoimmune process leading to small intestine mucosal injury. There is no approved treatment for CD. CNP-101*(TIMP-GLIA), a gliadin protein within a negatively charged polymer matrix of poly(DL-lactide-coglycolide (PLGA) nanoparticles, is a novel, first-in-class compound designed to induce tolerance to gluten in patients with CD. Aims & Methods: This Phase 2 double-blind randomized proof-of-concept study was designed to evaluate the efficacy and safety of CNP-101 8 mg/kg versus placebo in celiac patients. Treatments were administered intravenously on Day 1 and Day 8 for prevention of immune activation and small intestinal mucosal injury in adults with well-controlled biopsy-proven CD undergoing gluten challenge. Gluten challenge began 7 days after second treatment administration and included 12 g of gluten per day for 3 days followed by 6 g of gluten per day for 11 days. Endoscopy was performed before treatment and at the end of gluten challenge. The primary endpoint was change from baseline in interferon-gamma (IFN-) spot-forming units (SFUs) at Day 6 of gluten challenge using a gliadin-specific enzyme-linked immunospot (ELISpot) assay. Key secondary endpoints were changes from baseline in the villus height to crypt depth ratio (Vh:Cd), intestinal intraepithelial lymphocytes (IELs), peripheral gliadin-specific T-cell proliferation, cytokine secretion, and percentage of gut-homing CD4, CD8, and cells.
Results: A total of 34 patients were randomized and treated; six discontinued due to gluten-related symptoms, and 28 completed the 14-day gluten challenge per protocol. The primary study endpoint was achieved with mean change from baseline in IFN No patient had clinically significant changes in vital signs, routine clinical labs, or serum cytokines/chemokines, gliadin-specific T-cell proliferation and cytokine secretion. Plasma complement levels were raised in most patients; however, this transient effect was not reflected in associated adverse events. The most frequent AEs observed in CNP-101 treated patients with the corresponding value in parentheses for placebo-treated patients were: nausea 81% (72%), abdominal distension 56% (61%), diarrhea 50% (50%), headache 44% (17%), abdominal pain 38% (28%), abnormal gastrointestinal sounds 38% (39%), vomiting 31% (33%), fatigue 31% (50%), and back pain 31% (0).
Conclusion:
In this Phase 2 proof-of-concept study, CNP-101 (TIMP-GLIA) was able to prevent gluten challenge-induced immune activation in adults with CD. Contact E-Mail Address: luigi.laghi@humanitas.it Introduction: Delayed diagnosis affects the fate of patients with pancreatic ductal adenocarcinoma (PDAC). In addition, despite the advances in molecular typing, expression signatures exploitable for its diagnosis remain underdeveloped. Surprisingly, epithelial-to-mesenchymal Transition (EMT), the hallmark of PDAC spread in mechanistic models, remains widely untraced in humans. Aims & Methods: The aim of the study was to assess whether the levels of EMT transcription factors (TF) mRNAs in the blood of PDAC patients are increased, and if so whether they could serve as diagnostic tools. By quantitative real-time PCR, we assessed the levels (as normalized threshold cycles, ÁCt) of TWIST1, ZEB2, and CDH1 EMT-TF mRNAs in blood samples of 93 PDAC patients and 292 control subjects. Methods are covered by patent EP n.13197367.9. Results: Circulating mRNA levels of EMT-TFs were higher in patients, with a fold-change of 6.3 times for TWIST1, 10.6 times for ZEB2, and 6.0 times for CDH1 vs. controls. By ÁCt, the median of TWIST1 mRNA was 25.9 in patients vs. 28.3 in controls, that of ZEB2 mRNA 17.6 in patients vs. 22.0 in controls, and that of CDH1 23.6 vs. 26.4 (all p 5 0.0001, at rank-sum test). Consistently, the area under the curve (AUC) at receiver operating characteristic curve analysis was 0.94 for TWIST1, 0.88 for ZEB2, and 0.90 for CDH1 mRNAs. By cut-off values, 190 (65%) controls did not show any elevated messenger, a finding never occurring in patients. Conversely, all EMT-TF mRNAs were elevated in 60 (61.8%) patients but only in 10 (3.4%) controls (both p 5 0.0001). A regression model for PDAC diagnosis by EMT messengers identified 82 patients, (88.2% sensitivity) and 10 controls (96.6% specificity), with 0.98 AUC. Two-fold crossvalidation analysis returned an equal AUC (95% CI, 0.96-0.99). A sub-analysis restricted to 59 patients with stage I-II PDAC who underwent surgery also returned 0.98 AUC, with 86.4% sensitivity (eight false negative). Conclusion: Our study first demonstrates an enhanced expression of EMT-TF mRNAs in patients with PDAC, and shows that their high levels in blood efficiently discriminate PDAC patients, irrespectively of tumour respectability. These circulating messengers represent a candidate diagnostic tool, deserving further exploration in appropriate clinical settings. Disclosure: Luigi Laghi is granted as inventor in the EP n.13197367.9. In the current study, we explored (1) baseline liver transcriptome profiles of CHB and CHC patients with and without HCC development during long-term follow-up and (2) investigated their potential to predict HCC development. Charts from all CHB and CHC patients from five hepatology clinics were reviewed for the availability of a baseline, pre-antiviral treatment liver biopsy. Of these, 34 were diagnosed with HCC at a median of 8.3 (IQR 4.8-10.1) years after liver biopsy. Cases were split into four subgroups based on infecting virus (HBV/HCV) and cirrhosis status (yes/no) at baseline biopsy (Table 1) . Each subgroup of cases was matched for different demographic (e.g. gender and age at biopsy) and clinical (e.g. cirrhosis at biopsy and infecting virus) factors to a group of controls without HCC development during an equal or longer follow-up time. RNA derived from baseline biopsies (total n ¼ 72; Table 1 ) was subjected to RNA sequencing (RNAseq). Differentially Expressed Genes (DEG; Fold-change 41.5 and q 5 0.2) were called in each subgroup (Table 1) and a random forest classifier was trained to predict HCC development. Results: The total cohort consisted of 72 patients, of whom 34 developed a HCC during follow-up. Despite perfect matching for the clinical and demographic characteristics at baseline, at least 452 genes were differentially expressed between cases with and controls without future HCC development in each subgroup (Table 1 ). There was little overlap (510%) in DEG between cirrhotic CHB and CHC patients (Table 1) and non-cirrhotic CHB and CHC patients ( Table  1 ), suggesting that distinct processes leading to HCC oncogenesis may be triggered by these viruses. Among the top 20 up-and down-regulated genes in each subgroup, 40-75% have previously been linked to oncogenesis, underlining the biological relevance. Ingenuity Pathway Analysis showed an enrichment for the ''Wnt-catenin signalling'' pathway in the cirrhotic CHB group and the ''molecular mechanisms of cancer'' pathway in the non-cirrhotic CHC group. These results strongly suggest a genetic imprint for HCC development several years before clinical diagnosis. A random forest classifier tested with leave-one-outcross-validation was able to predict HCC development with an accuracy of 84.7%, a Negative Predictive Value of 92.1% and a Positive Predictive Value of 75.8% based on the subgroup and baseline expression levels of 20 genes, of whom several have previously been linked to hepatocarcinogenesis.
In this study, we are the first to identify distinct liver transcriptome profiles for patients with and without future HCC development at a median of 8.3 years before the HCC clinical onset. A 20-gene signature allowed us to accurately predict HCC development. Disclosure: Nothing to disclose. Contact E-Mail Address: roeyringel@gmail.com Introduction: Gastric electrical stimulation (GES) has been shown to reduce appetite, food intake and weight, thus leading to recent FDA approval of a surgically implanted gastrostimulator device for treatment of obesity.
However, surgically or endoscopically implanting gastrointestinal (GI) stimulating devices can be unnecessarily invasive and expensive. We conducted the firstin-human study to examine the safety, feasibility, and signals of efficacy of a novel ingestible gastric stimulation capsule (IGSC) system for the treatment of obesity. This first-in-human study is an extension of a previous safety and proofof-concept animal (pigs) study. Aims & Methods: Six males and females healthy volunteers, age 21 to 65 years, BMI 27 to 35 (overweight and class I obese) were enrolled into a 7-day, prospective, open-label randomized study. Study design included a 3-day screening period, followed by a 4-day treatment period, during which subjects ingested one IGSC on days 1 and 3. The capsules were programmed to apply intra-gastric and/or intestinal electrical stimulation, synchronized with subjects' meal schedule using the system's mobile app. Variables of interest for safety included integrity and natural expulsion of the capsule with bowel movement, all reported symptoms and adverse events, and 24 hours holter ECG monitoring. Efficacy measures included satiety and hunger levels, and response to a nutrient drink test. Following the drink test, patients were asked to score their hunger and satiety levels, on a 0-10 visual analog scale using the system's mobile app, at 30, 60, 120, and 180 minutes. A composite hunger/satiety score was calculated.
Results: All subjects expelled the IGSCs naturally. Seven adverse events (AEs) were reported; all were mild, short-lived, and self-resolving. One event of abdominal discomfort was considered likely related to the study treatment. The other six AEs were unrelated or likely unrelated to the study treatment. No clinically significant abnormal physical findings, laboratory measurements, or heart activities were recorded throughout the course of the study. The IGSC treatment was associated with a decrease in the volume of liquid ingested on the nutrient drink test. Strikingly, four of these individuals consumed an average of 27% less of the nutrient volume after receiving the IGSC treatment when compared with their no-treatment baseline. In addition, the IGSC treatment was associated with a considerable decrease in the hunger/satiety composite score compared with baseline. Conclusion: Gastric electrical stimulation via the non-invasive, IGSC system proved to be safe, feasible and well tolerated with no serious adverse events and no effect on heart activity. Our results suggest that GI stimulation using IGSC system may (1) reduce food intake as measured by total volume ingested by the nutrient drink test; and (2) reduce appetite as measured by the post nutrient drink hunger/satiety composite scores. This first of its kind IGSC system highlights the potential and provides the rationale for intraluminal GI electrical neuromodulation therapeutic approach. Specifically, the IGSC system could provide a safe, minimally invasive, non-chemical approach for treatment of obesity. Disclosure: This study was funded by Melcap Systems. YR is consultant for Melcap, AM is an employee of Melcap.
At the national level, USA had the highest prevalence rate (464.4 per 100,000 [95% UI 438-490]), followed by the UK (449.6 per 100,000 (GBD 2017) to analyse the incidence, mortality, and disability-adjusted life-years (DALYs) due to stomach cancer in 195 countries and territories from 21 regions and study the changes in these estimates between 1990 and 2017. The rates were standardised to the GBD world population and reported per 100,000 as age-standardised incidence rates (ASIR), age-standardised death rates (ASDR), and age-standardised DALY rates. All estimates were generated with 95% uncertainty intervals (UIs). ,000 more incident cases of stomach cancer, leading to nearly 96,000 more deaths. Despite the increase in absolute numbers, the worldwide age-standardised rates of stomach cancer (incidence, death, and DALYs) have declined since 1990. The drop in the disease burden showed a correlation with improved socio-demographic index. Globally, 38.2% of the DALYs were attributable to high-sodium diet in both sexes, and in men, 24.5% of the DALYs were attributable to smoking. Conclusion: Our findings provide insight into the changing burden of stomach cancer, which is useful in planning local strategies and monitoring their progress. To this end, specific local strategies should be tailored to each country's risk factor profile. Beyond the current decline in age-standardised incidence and death rates, a decrease in the absolute number of cases and deaths will be possible if the burden in East Asia, where currently almost half of the incident cases and deaths occur, is further reduced. Disclosure: Nothing to disclose. Contact E-Mail Address: malek@tums.ac.ir Introduction: Worldwide, both the incidence and death rates of pancreatic cancer (PC) are increasing. Evaluation of PC burden and its global, regional, and national patterns is crucial to policy making and better resource allocation for controlling PC risk factors, developing early detection methods, and providing faster and more effective treatments. Aims & Methods: Vital registration, vital registration-sample, and cancer registry data were used to generate the relevant estimates. Mortality, incidence, and disability-adjusted life-years (DALYs) were estimated and reported. All of the estimates were reported as counts and age-standardised rates per 100,000. 95% uncertainty intervals (UIs) were reported for all estimates. Results: In 2017, there were 447,000 (95% UI 438-456) incident cases of PC globally. The age-standardised incidence rate was 5.0 (4.9-5.1) per 100,000 in 1990 and increased to 5.7 (5.6-5.8) per 100,000 in 2017. There was a 2.3-times increase in number of deaths for both sexes from 196,000 (193-200) in 1990 to 441,000 (433-449) in 2017. In both 1990 and 2017, 52% of total incident cases
